Publications by authors named "Mingshi Pan"

Article Synopsis
  • Chemotherapy-induced myelosuppression (CIM) hinders blood cell production, making it a significant issue in cancer treatment.
  • Trilaciclib (TC) is the only FDA-approved CDK4/6 inhibitor that protects bone marrow by stopping the growth of certain cells, and its derivatives show strong potential as effective treatments for CIM.
  • Among these, one derivative displayed excellent inhibitory activity, low toxicity, great selectivity, and effective penetration into bone marrow, indicating it could improve treatment outcomes for individuals experiencing myelosuppression from chemotherapy.
View Article and Find Full Text PDF

Herein, a method to access 3-trifluoromethyl-1,4-benzoxazines from CF-imidoyl sulfoxonium ylides and 2-bromophenols has been demonstrated. This synthetic protocol proceeds a one-pot two-step sequence that includes the lithium-bromide-promoted O-H insertion of sulfoxonium ylides and annulation, and has the merits of broad substrate scope, excellent functional tolerance and operational simplicity, which provides an alternative means of obtaining CF-substituted heterocycles.

View Article and Find Full Text PDF

Herein, a new strategy for the direct synthesis of functionalized pyrroles from β-amino alcohols and ynones ruthenium-catalyzed acceptorless dehydrogenative coupling has been demonstrated. This developed methodology proceeds in an atom- and step-economic fashion together with the merits of broad substrate scope, operational simplicity, and water and hydrogen gas as the sole by-products, which provides an alternative and sustainable way to access functionalized pyrroles. Further, this method was applied to the rapid synthesis of the COX-1/COX-2 inhibitor and boron dipyrromethene derivative successfully.

View Article and Find Full Text PDF